Companies › Wayshine Biopharm
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| WSD0922-FU EGFR-TKI (third-generation) | EGFR | Phase 2 | Non Small Cell Lung Cancer; EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer; Non Small Cell Lung Cancer (NSCLC) | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06631989 | WSD0922-FU | Phase 1 | EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT06868485 | WSD0922-FU | Phase 2 | Non Small Cell Lung Cancer | Oncology | Sep 2027 |
| NCT07206498 | WSD0922-FU | Phase 1 | Non Small Cell Lung Cancer (NSCLC) | Oncology | Oct 2028 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Black Diamond Therapeutics Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical Jiangsu Alphamab Biopharmaceuticals Rakuten Medical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.